CD3-mediated activation of tumor-reactive lymphocytes from patients with advanced cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 98, Issue 12, 2001, Pages 6783-6788

  Hellström, Ingegerd ^a   Ledbetter, Jeffrey A ^a   Scholler, Nathalie ^a   Yang, Yi ^a   Ye, Zhengmao ^a   Goodman, Gary ^b   Pullman, Janice ^a   Hayden Ledbetter, Martha ^a   Hellström, Karl Erik ^a  

^a PACIFIC NORTHWEST RESEARCH INSTITUTE   (United States)

^b SWEDISH MEDICAL CENTER   (United States)

Author keywords

Immunotherapy; Transforming growth factor type 1; Tumor immunity; Tumor vaccines

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD40 ANTIGEN; GAMMA INTERFERON; LYMPHOKINE; MONOCLONAL ANTIBODY; T LYMPHOCYTE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA1;

ADVANCED CANCER; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; SENSITIZATION; T LYMPHOCYTE SUBPOPULATION; TUMOR IMMUNITY;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD28; ANTIGENS, CD3; ANTIGENS, CD40; COCULTURE TECHNIQUES; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; INTERFERON TYPE II; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; NEOPLASMS; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0035811007     PISSN: 00278424     EISSN: None     Source Type: Journal    
DOI: 10.1073/pnas.021557498     Document Type: Article

References (29)